Sign in to view content

Association of Ultra-Widefield Fluorescein Angiography-identified Retinal Nonperfusion With Risk of Diabetic Retinopathy Worsening Over Time

Paolo Antonio S. Silva, MD

Video
Published 2022

Related

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: One-Year Primary Outcomes From the Randomized RECOVERY Trial
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2019
Treatment Effect of Intravitreal Aflibercept Injection by Baseline Factors in Moderately Severe-to-Severe NPDR in PANORAMA
Nathan C. Steinle, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more